ang003
Cystic Fibrosis (CF)
Anagram Therapeutics, Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
81 Active assets in the Cystic Fibrosis (CF) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tezacaftor Vertex Pharmaceuticals Incorporated | Phase 4 | A |
Lumacaftor Hospices Civils de Lyon | Phase 4 | BBB |
Liprotamase Anthera Pharmaceuticals | Phase 4 | BBB |
Ivacaftor Meyer Children's Hospital IRCCS | Phase 4 | BBB |
ELEXACAFTOR Meyer Children's Hospital IRCCS | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
ang003 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →